GM-CSF, Sargramostim in Women With Recurrent Ovarian Cancer

Inclusion Criteria: * Patients must have a history of histologic or cytologic diagnosis of primary ovarian, primary peritoneal or tubal carcinoma. * Patients must be asymptomatic from their cancer. * Patients must have evidence of recurrent carcinoma, as determined by: * A rising cancer antigen 125 (CA-125) serum level greater than 35 U/mL or two successive rising values with the most recent value at least 3 times the nadir value. * Or evidence of evaluable or measurable disease by x-ray or computed tomography (CT) scan. * Patients may not receive concurrent antineoplastic therapy. All hormonal therapy used as a treatment modality (i.e. tamoxifen, arimidex, etc) must be stopped prior to treatment on protocol. * Age \> 18 years. * Eastern Cooperative Oncology Group (ECOG) performance status \< 2. Exclusion Criteria: * Known severe hypersensitivity to GM-CSF. * Other coexisting malignancies or malignancies diagnosed within the last 5 years, with the exception of basal cell carcinoma or cervical cancer in situ or concurrent superficial or stage IB endometrial carcinoma. * Concomitant use of anti-neoplastic therapy. * Treatment with a non-FDA approved or investigational drug within 30 days before Day 1 of trial treatment. * Any unresolved chronic toxicity greater then Common Toxicity Criteria (CTC) grade 2 from previous anticancer therapy (except alopecia). * Serum creatinine level greater than CTC grade 2 \[1.5 x upper limit normal (ULN)\]. * Pregnancy or breast feeding (women of childbearing potential). * Severe or uncontrolled systemic disease (e.g., unstable or uncompensated respiratory, cardiac, hepatic, or renal disease) as judged by the investigator. * Significant clinical disorder or laboratory finding that makes it potentially unsafe for the subject to participate in the trial as judged by the investigator. * Patients currently receiving other investigational antineoplastic agents, on systemic chemotherapy or under radiation therapy treatment. * Patients with clinical and/or radiographic evidence of current or impending bowel obstruction. * Performance status \< 1. * Ability to understand and the willingness to sign a written informed consent document.